Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Viatris Rolls Out 3 Follow-On AGs for Norvasc, Cardenalin, Relpax
Viatris Pharmaceuticals Japan said on March 5 that authorized generic (AG) versions are now available for the hypertension treatments Norvasc (amlodipine) and Cardenalin (doxazosin mesilate) and the migraine drug Relpax (eletriptan). Amlodipine Tablets/OD Tablets “Pfizer”, Doxazosin Tablets “Pfizer”, and Eletriptan…
To read the full story
Related Article
- Follow-On AGs Gaining Ground with 10 Launches in 2 Years, More Expected amid Generic Quality Concerns
September 9, 2021
- More Drug Makers Launching “Follow-on AGs”; Norvasc, Metgluco AGs Listed in December
December 18, 2020
- Authorized Generics for Lyrica, ComPlavin, Memary Dry Syrup Now Available
December 14, 2020
- Lyrica Faces Generic Debuts in Japan amid Patent Row: December Listing
December 10, 2020
- 22 Firms Get Approval for Lyrica Generics towards December Listing, Pfizer AG Included
August 18, 2020
BUSINESS
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Specialist Hails Wegovy as “Game Changer” for MASH Treatment
July 1, 2026
- Alfresa Boosts Stake in ENT Cell Sheet Startup
July 1, 2026
- Eisai, UCL Renew Neuroscience Alliance to 2030
July 1, 2026
- Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…